Genelux Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat solid tumor types. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus designed to selectively target and destroy cancer cells while stimulating immune responses. The company leverages its proprietary CHOICE discovery and development platform to engineer an extensive library of oncolytic vaccinia virus candidates with immune modulatory and enhanced cell-killing properties. Genelux Corp. targets cancers such as ovarian, lung, and pancreatic, addressing unmet needs in immuno-oncology through innovative virotherapy approaches. Operations are based in Southern California, with headquarters in Westlake Village. Founded in 2001, Genelux Corp. emphasizes clinical advancement of its pipeline to provide safe and effective treatments for solid tumors.